Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Becton, Dickinson and Company (BDX) — XLV Health Care · S&P 500 Profile |碧迪介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Becton, Dickinson and Company (BDX) — Business, History & S&P 500 Profile |碧迪介紹

Becton Dickinson company profile · medical devices, instruments & reagents · history · financial snapshot · S&P 500 rank #218 · 碧迪公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 30, 2026 (frozen benchmark)
Financials: FY2025 (ended Sep 30, 2025)
MARKET CAP
$53.90B
Oct 30, 2026 · Slickcharts (frozen benchmark)
S&P 500 WEIGHT
0.08%
Rank #218 · Oct 30, 2026 (Slickcharts)
FY2025 REVENUE
$21.84B
+8.2% YoY
FY2025 NET INCOME
$1.68B
FY2025 net income

SNAPSHOT

TickerBDX (NYSE)
CompanyBecton, Dickinson and Company
GICS sector / industryHealth Care (XLV) / Health Care Equipment & Supplies
S&P 500 rank (by weight)#218 · 0.08% (Oct 30, 2026)
Sector rank (by market cap)#27 in Health Care (Oct 30, 2026)
Share price (frozen benchmark)$197.88 (Oct 30, 2026)
HeadquartersFranklin Lakes, New Jersey
Founded1897 (by Maxwell Becton and Fairleigh S. Dickinson)
CEOTom Polen (Chairman, CEO and President)
Employeesabout 72,000 (2025)
Market cap$53.90B (Oct 30, 2026)

WHAT IT DOES

Becton, Dickinson — known as BD — is a global medical technology company that manufactures and sells medical devices, instrument systems and reagents used in drug delivery, diagnostics and research. Hospitals, laboratories and clinics use its syringes, catheters, diagnostic instruments and specimen-collection products every day.

The model is consumables plus instruments: single-use devices generate recurring revenue, while diagnostic and laboratory instruments place the consumables that follow. FY2025 revenues were $21,840M, up 8.2% from $20,178M, operating income was $2,578M and net income was $1,678M.

BD reports three segments — BD Medical, BD Interventional and BD Life Sciences — and its FY2025 figures here are as originally reported. A later portfolio separation (Biosciences and Diagnostic Solutions) recast later periods; the recast figures are not used in this profile.

BUSINESS SEGMENTS — FY2025 NET SALES

SegmentRevenueShareYoY
BD Medical———
BD Interventional———
BD Life Sciences———
Segment revenue split not stated in the sources used; units are listed qualitatively, with revenue, share and YoY shown as —. Do not read a split from this table.

HISTORY

YearMilestone
1897Founded in New York City by Maxwell Becton and Fairleigh S. Dickinson
1906Incorporated as Becton, Dickinson & Company
1962Initial public offering
2015Acquires CareFusion, expanding medication management
2017Acquires C. R. Bard, expanding interventional devices
2025FY2025 revenues reach $21,840M for the year ended Sep 30, 2025

COMPETITIVE POSITION

  • Consumables scale — single-use devices ship in enormous volumes to hospitals worldwide.
  • Installed instruments — diagnostic and laboratory systems lock in reagent and consumable sales.
  • Interventional growth — Bard products give exposure to faster-growing procedure markets.
  • Competition — Medtronic, Abbott, Boston Scientific and others contest device markets.
  • Pricing pressure — hospitals and group purchasing organizations negotiate hard on commodity devices.

FINANCIAL SNAPSHOT — FY2025

Total revenues$21,840M (+8.2% YoY)
Gross profit$9,925M
Operating income$2,578M
Net income$1,678M
Source: Becton, Dickinson FY2025 results (fiscal year ended Sep 30, 2025). Figures are as originally reported; later recasting after the portfolio separation is not applied here. Employee figure is the FY2025 count.

KEY RISKS

  • Portfolio separation — the spin-off execution and recasting complicate comparisons.
  • Pricing pressure — group purchasing organizations squeeze device prices.
  • Tariffs and supply chains — global manufacturing faces tariff and logistics costs.
  • Regulatory approvals — new devices need lengthy regulatory clearance.
  • Litigation — product-liability exposure follows medical devices.

WHY IT MATTERS FOR THE S&P 500

BD is the S&P 500's medical-consumables name: at a 0.08% index weight and #27 in Health Care by market cap, it is the index's main exposure to hospital consumables and diagnostic instruments.

Its volumes are a standing read on hospital activity — syringe, catheter and diagnostic demand moves with procedures before it shows up in hospital revenue.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Oct 30, 2026 close)
FinancialsBecton, Dickinson FY2025 Form 10-K results (fiscal year ended Sep 30, 2025), company profile sources
Sector classificationGICS (Health Care Equipment & Supplies) via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

BDX

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

代碼BDX(NYSE)
公司Becton, Dickinson and Company
GICS 板塊/行業醫療保健(XLV)/醫療保健設備與用品
標普500排名(按權重)#218 · 0.08%(2026 年 10 月 30 日)
板塊內排名(按市值)醫療保健第 #27(2026 年 10 月 30 日)
股價(凍結基準)$197.88(2026 年 10 月 30 日)
總部美國新澤西州富蘭克林湖
成立1897 年(Maxwell Becton 與 Fairleigh S. Dickinson 創辦)
行政總裁Tom Polen(董事長、行政總裁兼總裁)
員工約 72,000(2025 年)
市值$53.90B(2026 年 10 月 30 日)

業務概覽

Becton, Dickinson(簡稱 BD)是一家全球醫療科技公司,製造及銷售藥物輸送、診斷與研究用的醫療裝置、儀器系統與試劑。醫院、實驗室與診所每日使用其注射器、導管、診斷儀器與樣本採集產品。

其模式為耗材加儀器:一次性裝置帶來經常性收入,診斷與實驗室儀器則帶動後續耗材。FY2025 收入為 $21,840M,同比增長 8.2%(FY2024 為 $20,178M),營業利潤為 $2,578M,淨利潤為 $1,678M。

BD 申報三個板塊——BD Medical、BD Interventional 與 BD Life Sciences;此處 FY2025 數字按原申報列示。其後一次組合分拆(Biosciences 與 Diagnostic Solutions)重列了其後期間;重列數字本簡介不予採用。

業務板塊 — FY2025

板塊收入佔比同比
BD Medical———
BD Interventional———
BD Life Sciences———
板塊收入拆分未見於所用來源;本表只作定性列示,收入、佔比與同比均記為 —,請勿據此推斷拆分。

歷史沿革

年份里程碑
1897在紐約市創立,由 Maxwell Becton 與 Fairleigh S. Dickinson 創辦
1906註冊為 Becton, Dickinson & Company
1962首次公開招股
2015收購 CareFusion,擴大藥物管理業務
2017收購 C. R. Bard,擴大介入裝置業務
2025FY2025 收入達 $21,840M,財政年度截至 2025 年 9 月 30 日

競爭地位

  • 耗材規模——一次性裝置以龐大數量銷往全球醫院。
  • 已裝機儀器——診斷與實驗室系統鎖定試劑與耗材銷售。
  • 介入增長——Bard 產品帶來增長較快的手術市場敞口。
  • 競爭——Medtronic、Abbott、Boston Scientific 等爭奪裝置市場。
  • 定價壓力——醫院與集團採購組織對商品化裝置議價強硬。

財務快照 — FY2025

總收入$21,840M(同比 +8.2%)
毛利$9,925M
營業利潤$2,578M
淨利潤$1,678M
來源:碧迪 FY2025 業績(財政年度截至 2025 年 9 月 30 日)。數字按原申報列示;組合分拆後的重列不適用於此。員工數字為 FY2025 人數。

主要風險

  • 組合分拆——分拆執行與重列令比較複雜化。
  • 定價壓力——集團採購組織壓低裝置價格。
  • 關稅與供應鏈——全球製造面臨關稅與物流成本。
  • 監管審批——新裝置須經漫長的監管審批。
  • 訴訟——醫療裝置附帶產品責任敞口。

對標普500的重要性

碧迪是標普500的醫療耗材標的:指數權重 0.08%、醫療保健板塊市值第 #27,是指數對醫院耗材與診斷儀器的主要敞口。

其銷量是醫院活動的常設讀數——注射器、導管與診斷需求隨手術量變動,往往先於醫院收入反映。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 30 日收盤)
財務碧迪 FY2025 Form 10-K 業績(財政年度截至 2025 年 9 月 30 日)、公司簡介來源
板塊分類GICS(醫療保健設備與用品),據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

BDX

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · BDX
Data as of Oct 30, 2026 · Financials FY2025 (10-K) · Market data Oct 2026
Previous · Public Storage (PSA) — XLRE Real Estate · S&P 500 Profile |公共儲存公司介紹Next · Boston Scientific Corp. (BSX) — XLV Health Care · S&P 500 Profile |波士頓科學公司介紹

Entered 2026-10-31 11:40 · updated 2026-11-14 23:01 · rev 7